Abner Herrman & Brock LLC Sells 6,167 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Abner Herrman & Brock LLC lessened its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 24.9% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 18,591 shares of the medical research company’s stock after selling 6,167 shares during the period. Abner Herrman & Brock LLC’s holdings in Thermo Fisher Scientific were worth $9,700,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in TMO. Silicon Valley Capital Partners purchased a new position in Thermo Fisher Scientific in the first quarter worth $29,000. OLD Mission Capital LLC acquired a new position in Thermo Fisher Scientific during the 4th quarter valued at about $31,000. Live Oak Investment Partners acquired a new stake in Thermo Fisher Scientific in the fourth quarter worth about $36,000. Grey Fox Wealth Advisors LLC acquired a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at about $43,000. Finally, Barrett & Company Inc. purchased a new stake in Thermo Fisher Scientific during the 1st quarter worth approximately $43,000. 87.06% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 3,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 30th. The stock was sold at an average price of $557.77, for a total transaction of $1,673,310.00. Following the completion of the sale, the executive vice president now directly owns 17,556 shares in the company, valued at approximately $9,792,210.12. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 3,000 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, August 30th. The shares were sold at an average price of $557.77, for a total transaction of $1,673,310.00. Following the sale, the executive vice president now owns 17,556 shares of the company’s stock, valued at approximately $9,792,210.12. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Marc N. Casper sold 1,600 shares of the firm’s stock in a transaction dated Tuesday, August 8th. The stock was sold at an average price of $550.60, for a total transaction of $880,960.00. Following the completion of the transaction, the chief executive officer now directly owns 135,330 shares in the company, valued at $74,512,698. The disclosure for this sale can be found here. Insiders sold a total of 28,700 shares of company stock worth $15,799,270 in the last 90 days. Insiders own 0.32% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on TMO shares. Robert W. Baird dropped their price objective on shares of Thermo Fisher Scientific from $664.00 to $625.00 and set an “outperform” rating on the stock in a report on Thursday, July 27th. JPMorgan Chase & Co. raised their price objective on Thermo Fisher Scientific from $660.00 to $670.00 in a research note on Thursday, July 27th. StockNews.com lowered Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, September 2nd. Royal Bank of Canada lifted their price objective on shares of Thermo Fisher Scientific from $662.00 to $698.00 in a research note on Thursday, July 27th. Finally, KeyCorp cut their price objective on shares of Thermo Fisher Scientific from $710.00 to $640.00 in a research note on Thursday, May 25th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have given a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $631.71.

Thermo Fisher Scientific Price Performance

Shares of NYSE:TMO traded up $5.16 during trading on Thursday, reaching $516.06. 476,077 shares of the company’s stock traded hands, compared to its average volume of 1,473,844. The company has a quick ratio of 1.02, a current ratio of 1.42 and a debt-to-equity ratio of 0.67. Thermo Fisher Scientific Inc. has a fifty-two week low of $475.77 and a fifty-two week high of $609.85. The company has a 50-day simple moving average of $540.56 and a 200-day simple moving average of $542.09. The firm has a market cap of $199.17 billion, a PE ratio of 34.92, a P/E/G ratio of 2.51 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, July 26th. The medical research company reported $5.15 EPS for the quarter, missing analysts’ consensus estimates of $5.43 by ($0.28). Thermo Fisher Scientific had a net margin of 13.14% and a return on equity of 18.59%. The business had revenue of $10.69 billion during the quarter, compared to analysts’ expectations of $10.99 billion. During the same quarter last year, the firm earned $5.51 earnings per share. The firm’s quarterly revenue was down 2.6% compared to the same quarter last year. As a group, analysts predict that Thermo Fisher Scientific Inc. will post 22.37 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 13th. Stockholders of record on Friday, September 15th will be paid a dividend of $0.35 per share. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $1.40 dividend on an annualized basis and a dividend yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio is currently 9.57%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the United States and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, clinical next-generation sequencing, bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.